We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Joint Corp. (JYNT) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
The Joint Corp. (JYNT - Free Report) closed the most recent trading day at $15.94, moving -1.48% from the previous trading session. This change lagged the S&P 500's daily loss of 0.16%. At the same time, the Dow lost 0.07%, and the tech-heavy Nasdaq lost 0.52%.
Heading into today, shares of the company had lost 16.73% over the past month, lagging the Medical sector's gain of 4.4% and the S&P 500's gain of 3.12% in that time.
Investors will be hoping for strength from JYNT as it approaches its next earnings release. Our most recent consensus estimate is calling for quarterly revenue of $11.06 million, up 46.35% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.22 per share and revenue of $46.38 million. These totals would mark changes of +450% and +45.89%, respectively, from last year.
Any recent changes to analyst estimates for JYNT should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.22% lower within the past month. JYNT is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note JYNT's current valuation metrics, including its Forward P/E ratio of 73.54. Its industry sports an average Forward P/E of 14.64, so we one might conclude that JYNT is trading at a premium comparatively.
Also, we should mention that JYNT has a PEG ratio of 7.35. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - HMOs stocks are, on average, holding a PEG ratio of 1.04 based on yesterday's closing prices.
The Medical - HMOs industry is part of the Medical sector. This group has a Zacks Industry Rank of 16, putting it in the top 7% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JYNT in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Joint Corp. (JYNT) Dips More Than Broader Markets: What You Should Know
The Joint Corp. (JYNT - Free Report) closed the most recent trading day at $15.94, moving -1.48% from the previous trading session. This change lagged the S&P 500's daily loss of 0.16%. At the same time, the Dow lost 0.07%, and the tech-heavy Nasdaq lost 0.52%.
Heading into today, shares of the company had lost 16.73% over the past month, lagging the Medical sector's gain of 4.4% and the S&P 500's gain of 3.12% in that time.
Investors will be hoping for strength from JYNT as it approaches its next earnings release. Our most recent consensus estimate is calling for quarterly revenue of $11.06 million, up 46.35% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.22 per share and revenue of $46.38 million. These totals would mark changes of +450% and +45.89%, respectively, from last year.
Any recent changes to analyst estimates for JYNT should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.22% lower within the past month. JYNT is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note JYNT's current valuation metrics, including its Forward P/E ratio of 73.54. Its industry sports an average Forward P/E of 14.64, so we one might conclude that JYNT is trading at a premium comparatively.
Also, we should mention that JYNT has a PEG ratio of 7.35. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - HMOs stocks are, on average, holding a PEG ratio of 1.04 based on yesterday's closing prices.
The Medical - HMOs industry is part of the Medical sector. This group has a Zacks Industry Rank of 16, putting it in the top 7% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JYNT in the coming trading sessions, be sure to utilize Zacks.com.